A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of PT010, a Single Dose of PT009, and a Single Dose of Open-Label Symbicort(R) Turbohaler(R) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2018
Price : $35 *
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Budesonide/formoterol; Budesonide/formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Pearl Therapeutics
- 05 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 17 Jul 2014 New trial record